DK2414007T3 - Lægemiddelfremføringsanordning - Google Patents
Lægemiddelfremføringsanordning Download PDFInfo
- Publication number
- DK2414007T3 DK2414007T3 DK10711905.9T DK10711905T DK2414007T3 DK 2414007 T3 DK2414007 T3 DK 2414007T3 DK 10711905 T DK10711905 T DK 10711905T DK 2414007 T3 DK2414007 T3 DK 2414007T3
- Authority
- DK
- Denmark
- Prior art keywords
- piston rod
- nut
- drug delivery
- movement
- delivery device
- Prior art date
Links
- 230000007246 mechanism Effects 0.000 title claims description 23
- 230000033001 locomotion Effects 0.000 claims description 59
- 238000012377 drug delivery Methods 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 10
- 229920003023 plastic Polymers 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 230000005484 gravity Effects 0.000 claims 1
- 238000004439 roughness measurement Methods 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 50
- 108010011459 Exenatide Proteins 0.000 description 47
- 229960001519 exenatide Drugs 0.000 description 47
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 230000008878 coupling Effects 0.000 description 20
- 238000010168 coupling process Methods 0.000 description 20
- 238000005859 coupling reaction Methods 0.000 description 20
- 239000011295 pitch Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229940127215 low-molecular weight heparin Drugs 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229920000106 Liquid crystal polymer Polymers 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101000579646 Penaeus vannamei Penaeidin-1 Proteins 0.000 description 1
- 101000579647 Penaeus vannamei Penaeidin-2a Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- -1 polyoxymethylene Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31525—Dosing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3114—Filling or refilling
- A61M2005/3115—Filling or refilling spring-assisted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
- A61M5/31543—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose piston rod reset means, i.e. means for causing or facilitating retraction of piston rod to its starting position during cartridge change
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Claims (12)
1. Lægemiddelfremføringsanordning, der omfatter: - et legeme (4) med et rum (6) til et lægemiddel; en stempelstang (8) i legemet, hvilken stempelstang er bevægelig i forhold til legemet og er beregnet til at støde lægemidlet ud af rummet; - en mekanisme (11, 12, 13, 14), der er beregnet til at drive stempelstangen ved fremføring af lægemidlet, idet stempelstangen har en startposition i forhold til mekanismen; en anordning (14, 17, 25) til styring af bevægelsen af stempelstangen i forhold til legemet ved fremføring af lægemidlet, hvilken anordning til styring af bevægelsen af stempelstangen (8) omfatter en stempelstangsmøtrik (14); en anordning (15) til frigørelse af stempelstangen fra anordningen til styring af bevægelsen, hvilken anordning til frigørelse er beregnet til at muliggøre en nulstilling af stempelstangen til startpositionen, - et stopelement (13), der er beregnet til at forhindre en bevægelse af stempelstangen væk fra startpositionen, når stempelstangen er blevet frigjort, en anordning (13, 25) til fiksering af stempelstangsmøtrikken i forhold til legemet (4), hvilken anordning til fiksering af stempelstangsmøtrikken (14) i forhold til legemet (4) omfatter en kontramøtrik (13), hvilken kontramøtrik er stopelementet, - hvor anordningen til frigørelse af stempelstangen omfatter en fjeder (15), der er beregnet til at frigøre stempelstangsmøtrikken fra at være fikseret i forhold til legemet, hvor rummet (6) er beregnet til indsættelse af en patron (16), hvor patronen spærrer for stopelementet (13), og hvor stempelstangen (8) har en vægt, der nulstiller stempelstangen ved hjælp af tyngdekraften, når stempelstangen er frigjort, og lægemiddelfremføringsanordningen er indstillet på en sådan måde, at det får tyngdekraften til at drive stempelstangen mod startpositionen.
2. Lægemiddelfremføringsanordning ifølge krav 1, hvor stopelementet (13) er i indgreb med legemet (4) på en sådan måde, at en rotation af stopelementet i forhold til legemet forhindres.
3. Lægemiddelfremføringsanordning ifølge krav 1 eller 2, der yderligere omfatter: en rille (25) i legemet (4), hvilken rille styrer stopelementet (13); og en stopper (22) i rillen (25), der er beregnet til at blokere en bevægelse af stopelementet modsat bevægelsen af stempelstangen (8) under nulstilling.
4. Lægemiddelfremføringsanordning ifølge et af kravene 1 til 3, hvor anordningen (14, 17, 25) til styring af bevægelsen af stempelstangen (8) er beregnet til at koble stempelstangen med stopelementet (13), hvis der forekommer en bevægelse af stempelstangen væk fra startpositionen, når stempelstangen er blevet frigjort.
5. Lægemiddelfremføringsanordning ifølge et af kravene 1 til 4, der yderligere omfatter: en anordning (25) til forhindring af rotation af kontramøtrikken i forhold til legemet; - en anordning (17) til fiksering af stempelstangsmøtrikken (14) i forhold til kontramøtrikken (13); og - at fjederen (15) er anbragt ved kontramøtrikken (13) på en sådan måde, at fjederen medvirker til frigørelse af kontramøtrikken fra anordningen (17), der er beregnet til fiksering af stempelstangsmøtrikken i forhold til kontramøtrikken.
6. Lægemiddelfremføringsanordning ifølge et af kravene 1 til 5, hvor stempelstangen (8) og stempelstangsmøtrikken (14) er fremstillet af syntetiske materialer eller plastmaterialer, der har en værdi for koefficienten μ for gnidningsmodstand på højst 0,25 ved en relativ hastighed for de glidende overflader på 2 mm pr. sekund.
7. Lægemiddelfremføringsanordning ifølge et af kravene 1 til 6, hvor stempelstangsmøtrikken (14) er anbragt i kontakt med legemet (4); og legemet og stempelstangsmøtrikken er fremstillet af syntetiske materialer eller plastmaterialer, der har en værdi for koefficienten μ for gnidningsmodstand på højst 0,25 ved en relativ hastighed for de glidende overflader på 2 mm pr. sekund.
8. Lægemiddelfremføringsanordning ifølge et af kravene 1 til 7, der yderligere omfatter: - at stempelstangen (8) omfatter et gevind (9); - at stempelstangsmøtrikken (14) omfatter en skruegang, der svarer til gevindet på stempelstangen og går i indgreb med gevindet på stempelstangen; og - at stempelstangen (8) har en akse (18), hvor en tangent til en spiral, der dannes af gevindet (9) på stempelstangen, danner en vinkel på mindst 25° med aksen.
9. Lægemiddelfremføringsanordning ifølge krav 8, der yderligere omfatter: - et yderligere gevind (10) på stempelstangen (8); - at stempelstangen har en akse (18), hvor en tangent til en spiral, der dannes af gevindet (10) på stempelstangen, danner en vinkel på mindst 40° med aksen; - at mekanismen omfatter en drivbøsning (11) med en skruegang (12), der svarer til det yderligere gevind (10) på stempelstangen og går i indgreb med det yderligere gevind på stempelstangen; og at nulstillingen af stempelstangen til startpositionen omfatter en spiralbevægelse af stempelstangen i forhold til drivbøsningen (11) ifølge det yderligere gevind (10) på stempelstangen.
10. Lægemiddelfremføringsanordning ifølge krav 9, hvor stempelstangen (8) og drivbøsningen (11) er fremstillet af syntetiske materialer eller plastmaterialer, der har en værdi for koefficienten μ for gnidningsmodstand på højst 0,25 ved en relativ hastighed for de glidende overflader på 2 mm pr. sekund.
11. Lægemiddelfremføringsanordning ifølge et af kravene 6, 7 og 10, hvor de syntetiske materialer eller plastmaterialerne er forsynet med overflader, der har centerlinjegennemsnit for ruhedsmåling på mindre end 1,6 ym.
12. Lægemiddelfremføringsanordning ifølge et af ovennævnte krav, hvor patronen (16) indeholder et lægemiddel.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09004665 | 2009-03-31 | ||
| US16985209P | 2009-04-16 | 2009-04-16 | |
| PCT/EP2010/054342 WO2010115817A1 (en) | 2009-03-31 | 2010-03-31 | Drug delivery device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2414007T3 true DK2414007T3 (da) | 2015-06-08 |
Family
ID=40941562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10711905.9T DK2414007T3 (da) | 2009-03-31 | 2010-03-31 | Lægemiddelfremføringsanordning |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9555194B2 (da) |
| EP (1) | EP2414007B1 (da) |
| JP (1) | JP5701851B2 (da) |
| CN (1) | CN102448522B (da) |
| AU (1) | AU2010233830B2 (da) |
| BR (1) | BRPI1010237A2 (da) |
| CA (1) | CA2756578A1 (da) |
| DK (1) | DK2414007T3 (da) |
| IL (1) | IL215220A (da) |
| WO (1) | WO2010115817A1 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2475573C (en) | 2002-02-11 | 2013-03-26 | Antares Pharma, Inc. | Intradermal injector |
| CN101132820B (zh) | 2005-01-24 | 2010-05-19 | 安塔雷斯制药公司 | 预充式针辅助喷射注入器 |
| US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
| WO2007131013A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Two-stage reconstituting injector |
| EP2990067B1 (en) | 2008-03-10 | 2019-09-04 | Antares Pharma, Inc. | Injector safety device |
| EP3581224A1 (en) | 2008-08-05 | 2019-12-18 | Antares Pharma, Inc. | Multiple dosage injector |
| AU2010226442A1 (en) | 2009-03-20 | 2011-10-13 | Antares Pharma, Inc. | Hazardous agent injection system |
| WO2011101376A1 (en) * | 2010-02-18 | 2011-08-25 | Sanofi-Aventis Deutschland Gmbh | Clutch mechanism |
| US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
| US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
| AR088689A1 (es) * | 2011-11-09 | 2014-06-25 | Sanofi Aventis Deutschland | Conjunto de accionamiento para un dispositivo de administracion de medicacion y un dispositivo de administracion de medicacion que comprende un conjunto de accionamiento |
| HUE066117T2 (hu) | 2012-03-06 | 2024-07-28 | Antares Pharma Inc | Elõretöltött fecskendõ szakítóerõ-funkcióval |
| JP6457383B2 (ja) | 2012-04-06 | 2019-01-23 | アンタレス・ファーマ・インコーポレーテッド | テストステロン組成物の針支援式ジェット注入投与 |
| US9364610B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
| CN104334218B (zh) * | 2012-06-27 | 2017-06-20 | 赛诺菲-安万特德国有限公司 | 用于药物输送装置的阻塞件组合体 |
| EP4349383A3 (en) | 2013-02-11 | 2024-06-19 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
| EP2968792B1 (en) | 2013-03-11 | 2019-05-15 | Antares Pharma, Inc. | Dosage injector with pinion system |
| WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
| US9956349B2 (en) | 2013-05-21 | 2018-05-01 | Novo Nordisk A/S | Frontloaded drug delivery device with dynamic axial stop feature |
| CN105209095A (zh) | 2013-05-21 | 2015-12-30 | 诺和诺德股份有限公司 | 具有活塞杆联轴器的药物输送装置 |
| US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| US10722656B2 (en) * | 2015-01-28 | 2020-07-28 | Novo Nordisk A/S | Piston rod drive for an injection device |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA941881B (en) * | 1993-04-02 | 1995-09-18 | Lilly Co Eli | Manifold medication injection apparatus and method |
| US5536249A (en) * | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
| JP3387775B2 (ja) * | 1997-05-22 | 2003-03-17 | 株式会社大協精工 | 注射器用密封栓及びプレフィルド注射器 |
| US6899699B2 (en) * | 2001-01-05 | 2005-05-31 | Novo Nordisk A/S | Automatic injection device with reset feature |
| DE10229138B4 (de) * | 2002-06-28 | 2008-01-31 | Tecpharma Licensing Ag | Produktausschüttvorrichtung mit Kolbenstangen-Eilrücksetzung |
| GB0304823D0 (en) * | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| GB0304822D0 (en) * | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| US7169128B2 (en) * | 2003-08-04 | 2007-01-30 | Bioquiddity, Inc. | Multichannel fluid delivery device |
| CN101039713B (zh) * | 2004-10-14 | 2011-10-12 | 诺和诺德公司 | 具有剂量机构的注射装置 |
| ATE401921T1 (de) * | 2005-06-01 | 2008-08-15 | Shl Medical Ab | Medikamentenabgabevorrichtung |
| EP1923083A1 (en) | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Drive mechanisms for use in drug delivery devices |
| WO2008074897A1 (en) | 2006-12-21 | 2008-06-26 | Novo Nordisk A/S | A syringe device |
-
2010
- 2010-03-31 CN CN201080022703.4A patent/CN102448522B/zh not_active Expired - Fee Related
- 2010-03-31 EP EP10711905.9A patent/EP2414007B1/en not_active Not-in-force
- 2010-03-31 CA CA2756578A patent/CA2756578A1/en not_active Abandoned
- 2010-03-31 BR BRPI1010237A patent/BRPI1010237A2/pt not_active Application Discontinuation
- 2010-03-31 US US13/258,158 patent/US9555194B2/en not_active Expired - Fee Related
- 2010-03-31 AU AU2010233830A patent/AU2010233830B2/en not_active Ceased
- 2010-03-31 WO PCT/EP2010/054342 patent/WO2010115817A1/en not_active Ceased
- 2010-03-31 DK DK10711905.9T patent/DK2414007T3/da active
- 2010-03-31 JP JP2012502669A patent/JP5701851B2/ja not_active Expired - Fee Related
-
2011
- 2011-09-18 IL IL215220A patent/IL215220A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102448522B (zh) | 2014-06-04 |
| WO2010115817A1 (en) | 2010-10-14 |
| CN102448522A (zh) | 2012-05-09 |
| BRPI1010237A2 (pt) | 2016-10-18 |
| JP5701851B2 (ja) | 2015-04-15 |
| EP2414007A1 (en) | 2012-02-08 |
| HK1166728A1 (en) | 2012-11-09 |
| AU2010233830A1 (en) | 2011-10-20 |
| IL215220A (en) | 2015-09-24 |
| CA2756578A1 (en) | 2010-10-14 |
| EP2414007B1 (en) | 2015-03-04 |
| JP2012521827A (ja) | 2012-09-20 |
| US9555194B2 (en) | 2017-01-31 |
| AU2010233830B2 (en) | 2014-09-11 |
| IL215220A0 (en) | 2011-12-29 |
| US20120083748A1 (en) | 2012-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2414007T3 (da) | Lægemiddelfremføringsanordning | |
| US10398845B2 (en) | Drug delivery device | |
| US8939945B2 (en) | Drive mechanism for a drug delivery device | |
| DK2624894T3 (da) | Drivmekanisme til en lægemiddeldispenseringsanordning og lægemiddeldispenseringsanordning | |
| HK1166728B (en) | Drug delivery device | |
| CA2756583A1 (en) | Drug delivery device | |
| HK1166729A (en) | Drug delivery device | |
| HK1166729B (en) | Drug delivery device | |
| HK1169054B (en) | Drive mechanism for a drug delivery device | |
| HK1188152A (en) | Drive mechanism for a drug delivery device and drug delivery device | |
| HK1188152B (en) | Drive mechanism for a drug delivery device and drug delivery device |